Bee venom allergy: a recent trend among amateur beekeepers

Dinkel, Gwendolyn; Pietschke, Katharina; Belge, Katharina; Yazdi, Amir S.; Fischer, Jörg

doi:10.1007/s40629-017-0018-y

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… About 30% of patients treated for HVA require life-long VIT. This group includes patients suffering from co-morbidities such as mastocytosis, patients with severe initial systemic sting reactions, patients who have had systemic adverse events during VIT, but also individuals with high risks of future bee and/or wasp stings, such as beekeepers or workers in confectioneries [ 21 , 22 , 23 , 24 , 25 ]. …”

Section: Introductionmentioning

confidence: 99%

Venom Immunotherapy: From Proteins to Product to Patient Protection

Feindor

Heath

Hewings

et al. 2021

Toxins

View full text Add to dashboard Cite

In this review, we outline and reflect on the important differences between allergen-specific immunotherapy for inhalant allergies (i.e., aeroallergens) and venom-specific immunotherapy (VIT), with a special focus on Venomil® Bee and Wasp. Venomil® is provided as a freeze-dried extract and a diluent to prepare a solution for injection for the treatment of patients with IgE-mediated allergies to bee and/or wasp venom and for evaluating the degree of sensitivity in a skin test. While the materials that make up the product have not changed, the suppliers of raw materials have changed over the years. Here, we consolidate relevant historical safety and efficacy studies that used products from shared manufacture supply profiles, i.e., products from Bayer or Hollister–Stier. We also consider the characterization and standardization of venom marker allergens, providing insights into manufacturing controls that have produced stable and consistent quality profiles over many years. Quality differences between products and their impacts on treatment outcomes have been a current topic of discussion and further research. Finally, we review the considerations surrounding the choice of depot adjuvant most suitable to augmenting VIT.

show abstract